Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c038dd7da0e9a46b6bc7a2143a6fa083 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f07b4d301363c3f8d7bb89db60c7b233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4107e3a5e549bb7bd4005b12f25a3d35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ceade3381e2c3978de0631ce23754c2b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
filingDate |
2004-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5af3d5cb975b91918b28a2d8818aef1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5759b598a2baf205484b2bd003cf4ced http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d48d0419e32c98918ab161fdb38b345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34cd62352e37953212f2d554afaa471f |
publicationDate |
2006-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2006210620-A1 |
titleOfInvention |
Co-precipitated amorphous losartan and dosage forms comprising the same |
abstract |
The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the aqueous solution of losartan and one or more hydrophilic polymers to form a mixture. The amorphous losartan and one or more hydrophilic polymers are co-precipitated from the aqueous solution. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006160871-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017209372-A1 |
priorityDate |
2003-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |